LAUSR

Antitumor and antimetastatic effects of the medicinal herb Andrographis paniculata (AP) in esophageal cancer (EC) have been previously reported. In this study, we aimed to uncover the potential functional components and the underlying molecular mechanisms of AP in EC treatment using network pharmacology and experimental validation. Twenty‐two potential active AP compounds against EC were revealed, including the antitumor/antiinflammatory compounds panicolin, moslosooflavone, and deoxyandrographiside. Epidermal growth factor receptor (EGFR), signal transducer and activator of transcription 3 (STAT3), RAC‐alpha serine/threonine‐protein kinase (AKT1), prostaglandin‐endoperoxide synthase 2 (PTGS2), chemokine (C‐X‐C motif) ligand 8 (CXCL8), phosphatidylinositol 4,5‐bisphosphate 3‐kinase subunit alpha (PIK3CA), and toll‐like receptor 4 (TLR4) were most highly ranked among the predicted targets of AP in EC treatment and may play important roles in the anti‐EC effects of AP. KEGG pathway analysis revealed the enrichment of multiple cancer‐related pathways and signaling pathways. Quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR) and western blotting validation showed that overnight treatment with 850.3 μg/ml of AP water extract significantly reduced the mRNA expressions of EGFR and AKT in human EC‐109 cells. The presence of panicolin and moslosooflavone in the AP water extract samples were confirmed using LC‐MS against reference standards. This study has comprehensively revealed for the first time the potential functional components of AP in EC and explored the underlying molecular mechanisms. Future studies should characterize the potential pharmacological properties of the other highly ranked yet understudied compounds in AP detected.